Have you been diagnosed with Pulmonary Arterial Hypertension?

If you’ve answered “yes”, you may be eligible for the PAH-001 : A phase 1 clinical trial of ABI-009, a targeted mTOR inhibitor, for patients with severe pulmonary arterial hypertension (PAH)